Reading the immune system to rapidly diagnose disease

Immune IQ's point-of-care platform unleashes the power of the immune system to rapidly diagnose patients in minutes

The immune system detects virtually everything affecting a person's health, eclipsing any existing diagnostic technology. 
virus-g89474876d_1280.jpg

The immune system constantly monitors an individual's health and responds to evolving diseases. It can detect many cancers years before symptoms appear, and COVID-19 within hours of infection. 

The immune system serves as a comprehensive database of a patient's health status.

The information already exists...

...and we can decode it.

Immune IQ's point-of-care system goes beyond routine lab tests

Immune IQ has developed, in collaboration with Honeywell, the IQdx platform. It reads health status and disease information from a patient’s immune system to rapidly diagnose critical diseases, many not detectable today.

NextGen Instrument, PNG final.png

           IQdx  analyzer

holding card up.png

Disposable Test Card with Built-in Sample Preparation

Image by Uriel SC

Machine Learning Models

At the cusp of a diagnostic revolution...
Studio-Project.png

Our initial focus is on sepsis

Immune IQ's initial focus is on one of the world's greatest healthcare challenges - sepsis.

Our platform has the capabilities necessary to facilitate testing across most sites of care. Problem diseases can be addressed earlier, at a low cost, and with broad acceptance.

As the immune system becomes a primary tool for diagnosis,

Abstract Iceberg

why Immune IQ?

The IQdx enables broad adoption of immune-system-based diagnoses in most healthcare settings.

Immune IQ's powerful diagnostic approach has a much lower cost-per-test, greater range of disease identification and a shorter time to result than other cellular- and mRNA-based approaches.

Meet the Team

RBC banner.jpg
Management Team
DD.png

David Deetz

BR.png

Barbara Roth

AM.png

Andy Meltzer

Co-Founder & CEO

Previously founded two other medical device companies, one of which completed a successful IPO on NASDAQ and Deloitte identified as one of the fastest-growing medical device companies in the nation. The other was acquired by Danaher/ Radiometer as an important part of its POC product line. The author of 11 U.S. patents, David has raised $140 million in private and public capital for his companies.

Co-Founder & COO

Former medical technologist previously involved in two successful POC blood-testing startups. The first was purchased by J&J and the other, where she served as vice president of manufacturing, went public on NASDAQ.

VP Analytics & Software

Co-founded two tech start-ups in the retail predictive analytics space. Led multidisciplinary global teams providing financial analytics and petabyte scale financial data to banks and financial institutions around the globe, as well as migrating large-scale enterprise SaaS offerings to the cloud.

Scientific Advisory Board
JF.png

James Fackler, MD

AA.png

Amesh Adalja, MD

RI.png

Rick Ivey

1546912997212_edited.jpg

Ben Crocker, MD

Dr. Fackler is in Critical Care Medicine at Johns Hopkins Hospital.  He is a leader in the exponentially expanding field of artificial intelligence in medicine.

Dr. Adalja is a Senior Scholar at the Johns Hopkins Center for Health Security and a leading expert on COVID-19.

Mr. Ivey was the Worldwide VP of R&D Leader for the Becton Dickinson Diagnostic Systems for over 20 years. 

Dr. Crocker has been the Medical Director at Massachusetts General Hospital (MGH) where he heads its innovative primary care practice, Ambulatory Practice of the Future (APF).